Loading
AGR2 (Anterior gradient protein 2 homolog) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
Required for MUC2 post-transcriptional synthesis and secretion. May play a role in the production of mucus by intestinal cells. Proto-oncogene that may play a role in cell migration, cell differentiation and cell growth.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Tamoxifen.
In plain words · AGR2 (Anterior gradient protein 2 homolog) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
AGR2 (Anterior gradient protein 2 homolog) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
Required for MUC2 post-transcriptional synthesis and secretion. May play a role in the production of mucus by intestinal cells.
No product in this corpus aims at AGR2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA AGR2: RNA tissue enhanced (cervix 600 nTPM, intestine 1,148 nTPM, stomach 1 1,324 nTPM); high antibody staining in 18 normal tissues; highest cancer staining stomach cancer (12 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas AGR2 tissue; Open Targets ENSG00000106541 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Thompson D.A. et al, Biochem. Biophys. Res. Commun, 1998, "hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines". Source.
Sources: HGNC HGNC:328 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O95994 (protein name, function text, keywords and locations (REST API)); CIViC gene AGR2 (1 evidence items, 0 assertions, 1 variants; diseases: Breast Cancer (GraphQL API, CC0))
Required for MUC2 post-transcriptional synthesis and secretion. May play a role in the production of mucus by intestinal cells. Proto-oncogene that may play a role in cell migration, cell differentiation and cell growth. Promotes cell adhesion. Location: Secreted; Endoplasmic reticulum (UniProt). Locus 7p21.1 (HGNC).
RNA: tissue enhanced (cervix 600 nTPM, intestine 1,148 nTPM, stomach 1 1,324 nTPM), detected in many normal tissues.
Medium: Pancreas, Tonsil.
Medium only: thyroid cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"AGR2" OR ABSTRACT:"AGR2" OR TITLE:"anterior gradient 2, protein disulphide isomerase family member" OR ABSTRACT:"anterior gradient 2, protein disulphide isomerase family member" OR TITLE:"Anterior gradient protein 2 homolog" OR ABSTRACT:"Anterior gradient protein 2 homolog" OR TITLE:"XAG-2" OR ABSTRACT:"XAG-2" OR TITLE:"HAG-2" OR ABSTRACT:"HAG-2" OR TITLE:"AG2" OR ABSTRACT:"AG2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AGR2, not a curated reading list.